Turning the Page on the Monoamine Story: Utilizing the NMDA Pathway for Major Depressive Disorder

<p>Natalie T. Hagy, PharmD describes the monoamine and glutaminergic pathway for the treatment of major depressive disorder, recognizes response and remission rates of first line treatment for major depressive disorder and describes the clinical trials for dextromethorphan-bupropion and its impact on the landscape of major depressive disorder.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>